TP53 and cancer: In the present study, we describe the use 18F-FDG-PET/CT for cancer detection in 30 clinically asymptomatic TP53 mutation carriers undergoing continuous follow-up according to NCCN guidelines (2009 version) and with no diagnosis of cancer within 2 years preceding the study.